ArticleAnimal models and experimental medicine2025
A potential strategy for improving offspring behavior in maternal immune activation: Amantadine-mediated suppression of neuroinflammation.
Article in Animal models and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A potential strategy for improving offspring behavior in maternal immune activation: Amantadine-mediated suppression of neuroinflammation.Animal models and experimental medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMaternal viral infection during pregnancy can lead to maternal immune activation (MIA), increasing the risk of neurodevelopmental disorders in offspring. Amantadine (AMA) exhibits antiviral activity and is widely employed in the management of neurologic conditions. Nevertheless, the efficacy of AMA in treating MIA is currently not established.
methodsMIA was induced by polyinosinic acid-polycytidylic acid (poly(I:C)); AMA was administered from embryonic (E) day 11.5 for 3 days. BV-2 cells were stimulated using poly(I:C) and treated with AMA. Behavior was assessed via open field test, elevated plus maze test, three-chamber sociability test, and marble burying test. Neuronal morphology was vizualized using Nissl stain; apoptosis via TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) stain; protein expression (Iba1, NeuN, CD68, TNF-α [tumor necrosis factor-alpha], IL-1β [interleukin-1β]) using immunofluorescence (IF); interleukin-6 (IL-6) levels using enzyme-linked immunosorbent assay; reactive oxygen species using staining; Iba1, NeuN, Bcl-2, Bax, and cleaved caspase 3 using Western blot; and gene expression changes using RNA-seq.
resultsAMA treatment reduced the levels of IL-6 in maternal blood, improved autism-like behaviors in MIA offspring, and effectively prevented neuronal damage and neuroinflammation. In vitro cellular studies have demonstrated that AMA effectively downregulates the expression levels of pro-inflammatory cytokines, including IL-6, TNF-α, and IL-1β. RNA-seq analysis indicated that AMA mitigates abnormal activation of microglia by modulating inflammatory pathways associated with IL-6.
conclusionAMA can prevent the development of neuropsychiatric disorders in MIA offspring. This effect may be related to its ability to attenuate neuronal damage, reduce neuronal apoptosis, and inhibit neuroinflammation, indicating that the antiviral drug AMA may be a potential treatment for MIA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.